Abstract-The insulin resistance syndrome has been characterized by hypertension, upper body obesity, insulin resistance, hyperinsulinemia, glucose intolerance, and hypertriglyceridemia. Previous studies are inconsistent regarding the relationship between blood pressure and insulin resistance. We therefore compared the metabolic profile in 60 hypertensive subjects (meanϮSD arterial pressure, 116Ϯ7 mm Hg) and 60 normotensive subjects (mean arterial pressure, 88Ϯ5 mm Hg) matched for age, gender, and body mass index. Hypertensives had significantly higher waist-to-hip ratio than normotensives (Pϭ0.002). The groups did not differ in fasting plasma glucose
H ypertension has been associated with insulin resistance, hyperinsulinemia, glucose intolerance, dyslipidemia, and hypofibrinolysis, a condition known as the insulin resistance syndrome. [1] [2] [3] It has been argued that insulin resistance is involved in the pathogenesis of essential hypertension. [4] [5] [6] Compensatory hyperinsulinemia 7, 8 seen in insulin resistance is suggested to play a causal role in development of hypertension 7, 9 because hyperinsulinemia has been associated with proliferation of vascular smooth muscle cells, 10 increased renin output, 11 increased renal sodium retention, 12 and increased catecholamine secretion. 13 Hyperinsulinemia has also been associated with elevated activity of PAI-1, 3, 14 an inhibitor of fibrinolysis 15 that may predict future risk of myocardial infarction. 16, 17 Several epidemiological studies support the assumption that the plasma level of insulin is an independent risk factor for cardiovascular disease. 7,18 -20 On the other hand, other studies have not found any evidence that insulin is associated with cardiovascular disease. [21] [22] [23] Chronic insulin infusion in dogs does not raise the blood pressure, 24 and patients with insulinoma do not have alterations in blood pressure. 25 The inconsistencies in previous reports concerning metabolic derangements in hypertension and cardiovascular disease may be due to confounding factors such as age, gender, body weight, fat distribution, physical activity, diet, and other lifestyle factors. To study the role of insulin resistance and hyperinsulinemia in essential hypertension, we conducted a population-based study of the metabolic profile in 60 persons with long-standing, untreated, mild hypertension and 60 normotensive persons matched on individual basis for gender, age, and BMI.
Methods

Participants and Study Design
In 1986 through 1987, 81.3% (nϭ21826) of the men aged 20 to 61 years and the women aged 20 to 56 years living in Tromsø, Norway, participated in a health survey. 26 On the basis of that study, 156 persons with mild hypertension were enrolled in 1988 in a 10-week intervention trial with n-3 polyunsaturated fatty acids. 27 In 1991 these persons were invited to be examined at the Clinical Research Unit of the University Hospital of Tromsø for recruitment into the present study. Of the invited persons, 103 volunteered. Each completed a questionnaire about previous and present illnesses, family history, medication, diet, physical activity, and smoking and alcohol habits. A laboratory screening and measurements of blood pressure and body weight were also performed. Fifty-eight subjects were receiving no medication, had cholesterol levels between 6.0 and 8.9 mmol/L, systolic blood pressure Ͻ190 mm Hg, and diastolic pressure between 90 and 110 mm Hg on three separate occasions. None were diabetic, had ischemic heart disease, or were receiving antihypertensive drug treatment. These 58 persons participated in the present study together with 2 hypertensive subjects recruited from the primary healthcare services according to identical criteria. Each hypertensive volunteer was matched with a normotensive (diastolic blood pressure Ͻ85 mm Hg) participant in the same health survey 26 according to gender, age (within Ϯ2 years), and BMI (within Ϯ0.2 kg/m 2 ). The control subjects also had cholesterol levels within the same range as the hypertensive subjects. Each normotensive person completed the same questionnaire as their hypertensive match and had the same clinical and laboratory workup before enrollment into the study.
The study was approved by the Regional Board of Research Ethics, and each person gave written informed consent before participation. All studies were started at 8 AM after an overnight fast. The studies of each matched hypertensive and normotensive pair were performed on the same day in most cases or at a maximum of within 1 week. The participants followed a weight-maintenance diet for 3 days before the experiments and were asked to abstain from alcohol during this period.
Clinical and Laboratory Measurements
Three blood pressure measurements were recorded before the experiments on 2 separate days. The mean of the measurements was used in the analysis. Blood pressure was measured with a mercury sphygmomanometer after the participants had rested for 10 minutes, comfortably seated. Mean arterial pressure was calculated as diastolic pressure plus one third of the pulse pressure. The waist-to-hip ratio was calculated as body circumference at the level midway between the inferior border of the rib cage and superior border of the iliac crest, divided by the maximal circumference of the buttocks.
The blood was arterialized by keeping the subject's hand in a heating device at 65°C 28 ; blood was drawn from a cannulated dorsal hand vein without stasis. Fasting blood samples were drawn for determination of lipid profile and fibrinolytic variables. Glucose and insulin kinetics were assessed with an oral glucose tolerance test (1 g dextrose per kg body weight or a maximum of 75 g dextrose). Postload glucose and insulin responses were calculated as arbitrary incremental area units over the 2-hour sampling time. The molar ratio of C-peptide to insulin is an approximate indicator of insulin extraction in the liver 29 and was calculated as the molar ratio of incremental area under the C-peptide curve to the incremental area under the insulin curve during the oral glucose tolerance test.
On a separate day, a hyperglycemic clamp (glucose level, 10 mmol/L) 30, 31 was performed to assess insulin secretion and insulin sensitivity to glucose disposal and to suppression of NEFAs. Firstphase insulin release reflects the early insulin peak secreted from the pancreatic ␤-cells in response to glucose stimulation and was calculated as the area under the insulin curve over the initial 10 minutes of the hyperglycemic clamp. Second-phase insulin release reflects the ␤-cell function under sustained elevated glucose levels and was calculated as the area under the insulin curve from 120 to 180 minutes of the clamp. The efficiency of plasma insulin to induce increased glucose uptake was assessed as the insulin sensitivity index, calculated from the hyperglycemic clamp by dividing mean glucose infusion rate during the last hour of the clamp (mol ⅐ kg Ϫ1 ⅐ min 32 The difference between exogenous glucose infusion rate (mol ⅐ kg Ϫ1 ⅐ min
Ϫ1
) and the calculated appearance of glucose in plasma (mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ) equals the endogenous glucose production rate, which is assumed to be suppressed under clamp conditions.
We also did a euglycemic, hyperinsulinemic clamp 30 on 25 normotensive and 25 hypertensive participants on a third day to compare the insulin sensitivity indexes obtained from the two clamp techniques. Pearson correlation coefficient for the insulin sensitivity index calculated by the two clamp techniques was 0.79 (Pϭ0.0001).
Plasma glucose concentrations were analyzed at the bedside with a Yellow Spring Instruments glucose analyzer (2300 Stat Plus). Plasma insulin and C-peptide were measured by radioimmunoassay methods previously published. 33, 34 Proinsulin was measured with an immunofluorometric method as previously described 35 using monoclonal antibodies, one directed against insulin and another against C-peptide (PEP-001 and HUI-001 from Novo Nordisk). Glycosylated hemoglobin A 1C levels were measured by a liquid chromatographic procedure (Diamat system, Bio-Rad Laboratories GmbH). Serum cholesterol and triglycerides were measured on a Hitachi 737 Automatic Analyzer with a kit from Boehringer Mannheim. HDL cholesterol levels were determined according to the method described by Burstein et al. 36 VLDL cholesterol levels were calculated as 0.46 multiplied by the triglyceride level, and LDL cholesterol levels were calculated as total cholesterol minus the sum of VLDL and HDL cholesterol levels, according to the formula of Friedewald et al. 37 Apolipoprotein A 1 and B were measured by rate nephelometry, using the Array Protein System (Beckman Instruments Inc). Serum NEFAs were analyzed by using an acyl-CoA oxydase -based colorimetric kit (Wako Nefa C Kit, Wako Chemicals Gmbh).
For assessment of fibrinolysis, we measured PAI-1 activity with a commercial two-stage, indirect enzymatic kit (Spectrolyse, Biopool AB). 38 tPA activity was determined according to Wiman et al 39 as previously described. 40 Plasma fibrinogen was measured with an ACL 3000 Coagulation System manufactured by Instrumentation Laboratory SpA.
Statistical Analysis
All variables were checked with regard to frequency distribution. Skewed distributions were logarithmically transformed when appropriate. For each variable, the difference between the hypertensive and normotensive subjects was calculated as the value obtained in the hypertensive person minus the value in the normotensive person, by taking into account the individual matching. The average difference between the hypertensive and normotensive groups was calculated as the arithmetic mean (95% confidence interval) of the differences for the 60 pairs and was tested for statistical significance by one-sample t test. Associations between continuous variables were examined by computing the Pearson correlation coefficient, and multiple linear regression analyses were used to examine independent relationships. ANCOVA was used to adjust for differences in waist-to-hip ratio. In these analyses, we used each individual's value (nϭ120) and a dummy variable (0,1) to indicate hypertensive status. Two-factor ANOVA with an interaction term was used to examine whether differences among hypertensives and normotensives depended on gender. Frequency differences in categorical data obtained from the questionnaire were tested with the 2 test. Data are given as meanϮSD. PϽ0.05 was considered statistically significant. The data were analyzed using the SAS software package. 41 
Selected Abbreviations and Acronyms
BMI ϭ body mass index NEFA ϭ nonesterified fatty acid PAI ϭ plasminogen activator inhibitor tPA ϭ tissue plasminogen activator
Results
The hypertensive and normotensive groups were similar in age, smoking habits, physical activity, BMI, and cholesterol levels ( Table 1) . Body weights measured on the day of the experiments and at the screening examination 1 year before experiments were similar in both groups (data not shown), indicating that both groups had been weight stable before the experiments. Compared with control subjects, the hypertensive subjects had higher waist-to-hip ratio (Pϭ0.002) ( Table  1 ) and higher levels of fasting triglycerides (Pϭ0.01), VLDL cholesterol (Pϭ0.01) ( Table 2) , C-peptide (Pϭ0.004), and proinsulin (Pϭ0.01), as well as 2-hour postload levels of glucose (Pϭ0.011) and insulin (Pϭ0.015) ( Table 3) . Waistto-hip ratio was significantly and similarly associated with the metabolic variables that differed in the hypertensive and normotensive groups (data not shown). When controlling for waist-to-hip ratio (by ANCOVA with hypertensive status as factor and waist-to-hip ratio as covariate), there were no longer any significant differences between the hypertensive and normotensive subjects in levels of triglycerides (Pϭ0.21), VLDL cholesterol (Pϭ0.21), C-peptide (Pϭ0.42), proinsulin (Pϭ0.15), and postload glucose (Pϭ0.26) and 
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insulin (Pϭ0.46). Inclusion of waist-to-hip ratio in the models gave a significant increase in R 2 , ie, the overall error variance was lowered.
Subgroup analysis according to gender showed that the hypertensive and normotensive women were similar in waistto-hip ratio and metabolic variables, whereas the hypertensive and normotensive men differed significantly both in waistto-hip ratio and the metabolic variables (Table 4 ). There was no statistically significant interaction by 2-factor ANOVA (Table 4 ).
In the subgroup of participants in whom glucose turnover was measured, the hypertensives (nϭ23) were found to have a higher endogenous glucose production during the clamp than their normotensive controls (nϭ23; Pϭ0.02) ( Table 3) . The insulin levels during the clamp were 247Ϯ160 and 217Ϯ131 pmol/L (PϾ0.3), and the rates of total glucose appearance were 34.83Ϯ12.71 and 33.34Ϯ13.64 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 (PϾ0.30), respectively. Adjustment of the endogenous glucose production rate for differences in insulin levels during the clamp did not influence the results, but standardizing for group differences in waist-to-hip ratio eliminated the differences in endogenous glucose production (adjusted means, 2.34 and 2.10 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 , respectively; Pϭ0.3).
The hypertensive and normotensive groups were similar both in insulin sensitivity to glucose disposal and NEFA suppression (Table 3) . No correlations between blood pressure and insulin sensitivity index, percentage of NEFA suppression, fasting and postload glucose and insulin levels, or proinsulin levels were observed in separate analyses of the 2 groups and in the total study population. The relationships between the insulin sensitivity index and BMI were similar in the hypertensive (rϭϪ0.59, Pϭ0.0001) and normotensive (rϭϪ0.58, Pϭ0.0001) groups (Figure 1) , and waist-to-hip ratio was also similarly associated with the insulin sensitivity index in the two groups (rϭϪ0.32, Pϭ0.05 and rϭϪ0.39, Pϭ0.05, resepctively; rϭPearson correlation coefficient) (Figure 2) . BMI (Pϭ0.0001) and waist-to-hip ratio (Pϭ0.05) were independent predictors of insulin sensitivity for glucose disposal when included as predictor variables in a multiple Values are meanϮSD or mean (95% confidence interval [CI]). C-peptideϺinsulin ratio after glucose challenge indicates molar ratio of area under C-peptide curveϺarea under insulin curve; 1st-phase insulin release, area under insulin curve during initial 10 minutes of hyperglycemic clamp; 2nd-phase insulin release, area under insulin curve during 120 to 180 minutes of hyperglycemic clamp; NEFA suppression, percent reduction of NEFA levels at 120 to 180 minutes during hyperglycemic clamp compared with baseline NEFA levels; endogenous glucose production during clamp, difference between exogenous glucose infusion rate (mol ⅐ kg Ϫ1 ⅐ min
Ϫ1
) and rate of appearance of glucose calculated from plasma 3-[ 3 H]glucose specific activities (mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ) at 120 to 180 minutes during hyperglycemic clamp, measured in 23 hypertensive subjects and 23 normotensive subjects. Insulin sensitivity is calculated as mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ⅐ pmol/L. *Value in hypertensive subject minus value in normotensive subject.
linear regression model together with mean arterial pressure and age (data not shown).
In pooled analyses of both study groups, fasting and postload glucose levels correlated with mean arterial pressure (rϭ0. 17 45, Pϭ0.0001) . Of these variables, only waist-to-hip ratio showed a statistically significant association with glucose levels when they were included as predictor variables in a multiple linear regression model.
The hypertensive and normotensive groups did not differ in NEFA levels, levels of LDL and HDL cholesterol, apolipoprotein A and B, or fibrinolytic variables such as PAI-1 activity (Table 2) .
Discussion
The present population-based study suggests that hypertension per se is not associated with impaired insulin sensitivity or with fasting hyperinsulinemia. Our study also indicates that body fat distribution, as measured by waist-to-hip ratio, may be concerned in the pathogenesis of the metabolic derangements observed in essential hypertension. We studied a fairly large group of stable hypertensive and normotensive subjects recruited from a population health survey 26 with a high attendance rate (81.3%), and the two groups were well balanced for potentially confounding factors. A large proportion of all persons who had untreated, stable hypertension after the health survey were screened for recruitment into the present study, and all subjects fulfilling the inclusion criteria participated. The normotensive control subjects were selected from participants from the same population study as the hypertensive subjects, and it is unlikely that the limited number of matching variables (gender, age, and BMI) would result in the selection of a particular subgroup of normotensive persons who did not reflect the distribution of the metabolic variables in the normotensive population as a whole. The generalizability of the present results therefore appears sound.
Our data demonstrate that even if the effect of BMI is well accounted for in studies on insulin sensitivity, small differences in waist-to-hip ratio may still influence the results. The waist-to-hip ratio may have a strong impact on variables associated with insulin sensitivity because accumulation of visceral fat increases the hepatic NEFA flux 42 and leads to altered insulin clearance 43 and hyperinsulinemia. 29 Hyperinsulinemia may downregulate the peripheral insulin receptors. 44, 45 Increased oxidative NEFA turnover in the liver drives the gluconeogenesis 46 and may cause impairment in hepatic sensitivity to insulin. 47 Increased nonoxidative NEFA turnover leads to augmented VLDL and triglyceride synthesis. 48, 49 Higher rates of both nonoxidative 50 and oxidative 46 NEFA turnover impair insulin sensitivity to glucose disposal. The amounts of visceral fat and total body fat are determinants of the NEFA production rate 49 and are therefore closely related to insulin sensitivity. It is crucial to take this into account in the investigation of a possible causal role of insulin or insulin resistance in the pathogenesis of essential hypertension. The assumption that plasma insulin level is associated with raised blood pressure and cardiovascular disease is based on the results of studies 7,18 -20 where either fasting 7, 18 or postload 7, 19, 20 insulin levels were associated with hypertension 7 and coronary heart disease. 18 -20 In these studies, the degree of insulin resistance was defined by hyperinsulinemia and was not measured directly by clamp technique. Other variables, such as waist-to-hip ratio, BMI, or triglyceride and NEFA levels, were either insufficiently 7, 19, 20 or not 18 controlled for. The inconsistencies in these studies may be due to variations in lipid metabolism, since hyperinsulinemia during elevated NEFA flux could be the result of reduced hepatic clearance 29, 43 and not necessarily a compensation for impaired insulin sensitivity.
Only a few clamp studies have been done to assess insulin sensitivity in hypertension. 4, 5, 51 Ferrannini et al 4 found a 40% reduction in nonoxidative glucose disposal in 13 young hypertensive subjects compared with controls with comparable BMI and percentage of body fat. Unfortunately, data for waist-to-hip ratio and triglyceride levels were not given. However, the finding of increased lipid oxidation during the clamp in the hypertensive group indicates that there were differences in lipid metabolism that could account for the impairment in insulin sensitivity, rather than elevated blood pressure per se. Pollare et al 5 have done extensive clamp studies of 58 lean and 85 obese hypertensive subjects, and they reported that lean and obese hypertensives had a 20% and 40% reduction in glucose disposal rate, respectively. Both the lean and the obese hypertensives, however, had considerably higher serum lipid levels and higher waist-tohip ratios compared with the control subjects. The measurements of insulin sensitivity were not adjusted for differences in serum lipids. Another clamp study 51 showed that obese hypertensive persons had the same degree of insulin resistance as obese normotensive subjects. This observation is in keeping with the present study.
The finding that BMI and waist-to-hip ratio predict insulin sensitivity, whereas blood pressure is not associated with insulin sensitivity, suggests that elevated blood pressure is a bystander in the development of insulin resistance. The important role of increased hepatic NEFA flux due to abdominal fat accumulation in the development of insulin resistance has been demonstrated in a recent Finnish study, 52 in which 12% of a nondiabetic population had a mutation of the ␤ 3 -adrenergic receptor gene in visceral fat. Persons with this type of mutation have increased abdominal fat deposition and thus elevated NEFA flux to the liver. 42 These persons were found to have increased waist-to-hip ratio, higher blood pressure levels, increased insulin response after glucose challenge, and decreased glucose disposal during clamp studies compared with persons without this mutation. A recent prospective study of 4089 subjects 53 further illustrates the importance of NEFA in the glucose homeostasis. High concentration of plasma NEFA is reported to be a risk factor for future glucose intolerance independent of age, waist-tohip ratio, BMI, and fasting or postload insulin levels.
In the present study, the hypertensive subjects tended to have higher glucose levels than the control subjects. An independent relationship between blood pressure and plasma glucose was observed in the Paris Prospective Study. 18 It has been speculated that hyperglycemia may have a direct stimulatory effect on the sympathetic nervous system 54 or may ). The associations between waist-to-hip ratio and insulin sensitivity index are expressed as Pearson correlation coefficients. R 2 (by linear regression) was 0.11 in the hypertensive group and 0.14 in the normotensive group.
lead to hypertension through oxidative stress caused by glycation of proteins. 55 Our data showed that hypertension was not associated with glucose levels when waist-to-hip ratio was controlled for and that waist-to-hip ratio predicted glucose levels independently of blood pressure. This suggests that the higher glucose levels were related to increased hepatic NEFA turnover and increased hepatic glucose production rather than to elevated blood pressure. The finding that hypertensive subjects who underwent tracer studies did not have completely suppressed hepatic glucose production during hyperglycemic clamp was unexpected. The ongoing endogenous glucose production was not accounted for in the calculation of insulin sensitivity index, since we had these data for a subgroup of the study population only. We may therefore have underestimated the insulin sensitivity index, which means that the hypertensive subjects were even more sensitive to insulin in nonhepatic tissue than stated in the present study.
It has been suggested that insulin precursors may differ from insulin in biological effects and may therefore be more important than insulin in predicting vascular disease. 56 In the present study, fasting levels of C-peptide and proinsulin were higher in hypertensive than in normotensive subjects. Since the differences did not persist after adjustment for waist-tohip ratio, we believe that the levels of C-peptide and proinsulin in the hypertensive group were higher because the efficiency to clear these substances was impaired by raised lipid flux.
In summary, we find that well-matched hypertensive and normotensive persons do not differ in insulin sensitivity and that BMI and waist-to-hip ratio are closely linked to insulin sensitivity, regardless of blood pressure status. We suggest that raised NEFA turnover associated with increments in BMI and waistto-hip ratio causes the deterioration in insulin sensitivity often observed in hypertension. Increments in BMI and waist-to-hip ratio also increase the tendency to develop hypertension. It seems that there are two parallel mechanisms whereby BMI and waist-to-hip ratio are key factors affecting both blood pressure and insulin sensitivity in a deleterious way.
